Brucellosis is an important malady of productive and wildlife animals and a worldwide 3 zoonosis. The use of effective vaccines and the corresponding diagnostic tests that allow 4 differentiating infected from vaccinated animals are essential tools to control the disease. For 5 this, a prototype of Brucella abortus S19 vaccine expressing green fluorescent protein (S19-6 GFP) was constructed. The S19-GFP was readily identified under ultraviolet light by 7 macroscopic and microscopic examination and maintained all the biochemical characteristics 8 of the parental S19 vaccine. S19-GFP replicated ex vivo and in vivo, and protected mice 9 against challenge with virulent B. abortus to the same extent as the isogenic S19. An 10 immunoenzymatic assay designed to measure anti-GFP antibodies allowed the discrimination 11 between mice vaccinated with S19-GFP and those immunized with S19. Both vaccines raised 
The use of green fluorescent protein as a marker for Brucella vaccines Brucellosis is a disease of terrestrial and marine mammals and an important zoonosis [1] . 
17
Although these approaches minimize the diagnostic problems of differentiating infected from 18 vaccinated cattle, they do not solve the serological interferences [12, 13] .
19
An alternative strategy to avoid the serological interference has been the development of LPS and GFP was evaluated in sera of S19-GFP (n=25), 2308-GFP (n=25) or S19 (n=25)
22
vaccinated inoculated mice, using as negative reference sera of PBS injected control animals
23
(n=5) and bled at different times after infection. Comparison of S19-GFP with the respective isogenic S19 demonstrated no significant reported interaction of S19 with host cells (Fig. 1B) . Similarly, S19-GFP replicated to the 21 same extent as its parental strain in HeLa cells and in macrophages (Fig. 1C) . All CFU 22 recovered from S19-GFP infected macrophages or HeLa cells were fluorescent,
demonstrating the stability of the construct.
24
B. abortus S19 follows distinctive replication kinetics in mice, and induces significant levels 1 of protection after challenge with virulent strains [41] . The replication profile of S19-GFP 2 shows a characteristic peak at 14 days of infection paralleling the replication profile of the 3 isogenic S19 reference strain ( Fig. 2A) . In addition, S19-GFP vaccinated mice showed a 4 similar level of protection against challenge with virulent B. abortus 2308 than S19 (Fig. 2 B) .
5
In cases in which few colonies of S19-GFP were present in challenged animals, they were 6 readily resolved from the B. abortus 2308 by fluorescence, without the need of a selective 7 bacteriological agar media. 
B. abortus S19-GFP induces antibodies against LPS and GFP

10
The rational for using a S19-GFP vaccine relies partly on its potential for inducing anti-GFP antibodies to the GFP antigen and the enzymatic reaction (Fig. 3A) . All the mice vaccinated 19 with S19-GFP or infected with 2308-GFP produced significant levels (p<0.001) of antibodies 20 against GFP, already detectable at three weeks after inoculation and persistent up to the end of 21 the experiment at 12 weeks after infection (Fig. 3B) . All mice injected with S19-GFP showed 22 significantly higher antibody titers (p< 0.001) against GFP during the 12 weeks of the assay 23 than mice infected with B. abortus 2308-GFP (Fig. 3B ). The differences in antibody
Brucella-GFP vaccines production between mice vaccinated with S19-GFP and those infected with 2308-GFP, were 1 not due to different expression of GFP between both strains, as demonstrated by 2 immunodetection of this protein in bacterial lysates (Fig. 3D3C) . Moreover, no cross with the parental S19 strain, eventually antibodies leveled up at later times (Fig. 3D) . this regard it is worth noting that vaccinated mice with S19-GFP consistently generated higher 22 levels of antibodies than the 2308-GFP infected animals, despite of the fact that both strains 23 expressed similar quantities of GFP (Fig. 3) . Interestingly, B. abortus S19 vaccinated cattle
13
Brucella-GFP vaccines consistently produce lower levels of antibodies against the LPS antigen than infected animals 1 [2, 7, 9], an event that seems to be reversed in the case of anti-GFP antibodies, at least in the 2 murine model used here. Therefore, the manner in which brucellosis infection proceeds seems 3 to be a relevant factor for the production of antibodies against GFP and LPS.
4
The S19-GFP vaccine in addition to induce antibodies against the GFP marker antigen, it 5 possesses other advantages that eventually could be extrapolated to alternative GFP anti-
6
Brucella vaccines, such as Rev1. First, the S19-GFP is easily distinguished from other infected from S19 or Rev1 vaccinated animals will remain functional. This is important 16 because some of these tests are able to distinguish abortions and bacterial shedding due to 17 exacerbated infections with the vaccine strain [47] . And last but not least, it is likely that these 18 vaccines are eagerly accepted by farmers and agriculture authorities, due to the already 19 recognized immunogenic and protective properties of its parent S19 or Rev1 reference strains.
20
The S19-GFP vaccine studied here is a prototype, containing a non-integrative plasmid that 21 expresses GFP constitutively and owns an antibiotic resistant cassette. In addition it was 22 tested in mice, widely used in experimental brucellosis, but which do not correspond to the 23 natural hosts. In conclusion, our approach constitutes a "proof of concept" demonstrating that (Mø) after 48 h of infection (C). Experiments were repeated at least three times. 
